LOGIN  |  REGISTER
C4 Therapeutics
Cue Biopharma

Baxter to Present at Morgan Stanley 21st Annual Global Healthcare Conference

August 29, 2023 | Last Trade: US$29.59 0.01 0.03

DEERFIELD, Ill. / Aug 29, 2023 / Business Wire / Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023. José (Joe) E. Almeida, Baxter’s chairman, president and chief executive officer, is scheduled to present at 9:30 a.m. Eastern Time.

The live webcast of Baxter’s presentation can be accessed at www.baxter.com and will be available for replay through March 13, 2024.

About Baxter

Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of diagnostic, critical care, kidney care, nutrition, hospital and surgical products used across patient homes, hospitals, physician offices and other sites of care. For 90 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, digital health solutions and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

Assertio

Stock Quote

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

End of content

No more pages to load

Next page